Tandem Diabetes Care, a medical device company, said pre-market Tuesday that it has obtained a U.S. patent titled “preventing inadvertent changes in ambulatory medical devices”.
The patent relates to important safety features for the prevention of inadvertent changes in touchscreen enabled ambulatory infusion pumps, including insulin pumps. The touchscreen may be on the pump itself or be in wireless communication with a pump. “We are the first and only company to receive FDA approval of an insulin pump with a touchscreen,” CEO Kim Blickenstaff said in a statement. “This patent significantly strengthens our intellectual property position surrounding Tandem’s user interface and the implementation of important features in other ambulatory infusion pumps that utilize touchscreen control.